Pathogenic Mechanisms of Bradykinin Mediated Diseases. Dysregulation of an Innate Inflammatory Pathway.

Advances in Immunology

Volumn 121, Issue , 2014, Pages 41-89

  Kaplan, Allen P ^a   Joseph, Kusumam ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Angioedema; Bradykinin; C1 inhibitor; Factor XII; Kallikrein; Kininogen

Indexed keywords

ADRENALIN; AMINOCAPROIC ACID; ANDROGEN; ANTIFIBRINOLYTIC AGENT; ANTIHISTAMINIC AGENT; BLOOD CLOTTING FACTOR 12; BRADYKININ; COMPLEMENT COMPONENT C1; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C1S INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; CYTOKERATIN 1; DANAZOL; ICATIBANT; KALLIKREIN; KININOGEN; OMALIZUMAB; STANOZOLOL; STEROID; TRANEXAMIC ACID; UROKINASE; ZINC;

ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ARTICLE; ASTHMA; BINDING SITE; CHRONIC URTICARIA; CLINICAL FEATURE; COMPLEMENT DEFICIENCY; ENZYME ACTIVITY; HUMAN; IMMUNE DYSREGULATION; IMMUNOPATHOGENESIS; INNATE IMMUNITY; INTRACELLULAR SIGNALING; LIVER CELL CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS; RHINITIS; URTICARIA; VIRILIZATION;

ANGIOEDEMA; BRADYKININ; C1 INHIBITOR; FACTOR XII; KALLIKREIN; KININOGEN;

ANGIOEDEMAS, HEREDITARY; ANIMALS; BRADYKININ; COMPLEMENT C1 INHIBITOR PROTEIN; ENDOTHELIUM, VASCULAR; FACTOR XII; HUMANS; IMMUNITY, INNATE; INFLAMMATION; INFLAMMATION MEDIATORS; KININOGEN, HIGH-MOLECULAR-WEIGHT; PREKALLIKREIN; SIGNAL TRANSDUCTION;

EID: 84891351888     PISSN: 00652776     EISSN: 15578445     Source Type: Book Series    
DOI: 10.1016/B978-0-12-800100-4.00002-7     Document Type: Chapter

References (176)

1. Austen K., Sheffer A. Detection of hereditory angioneurotic edema by demonstration of a reduction in the second component of human complement. New England Journal of Medicine 1965, 272:649-656.
2. Baird T.R., Walsh P.N. Activated platelets but not endothelial cells participate in the initiation of the consolidation phase of blood coagulation. Journal of Biological Chemistry 2002, 277(32):28498-28503.
3. Baird T.R., Walsh P.N. Factor XI, but not prekallikrein, blocks high molecular weight kininogen binding to human umbilical vein endothelial cells. Journal of Biological Chemistry 2003, 278(23):20618-20623.
4. Bajzar L., Manuel R., Nesheim M.E. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. Journal of Biological Chemistry 1995, 270(24):14477-14484.
5. Bajzar L., Morser J., Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. Journal of Biological Chemistry 1996, 271(28):16603-16608.
6. Beierwaltes W.H., Carretero O.A., Scicli A.G., Vavrek R.J., Stewart J.M. Competitive analog antagonists of bradykinin in the canine hindlimb. Proceedings of the Society for Experimental Biology and Medicine 1987, 186(1):79-83.
7. Bergamaschini L., Parnetti L., Pareyson D., Canziani S., Cugno M., Agostoni A. Activation of the contact system in cerebrospinal fluid of patients with Alzheimer disease. Alzheimer Disease and Associated Disorders 1998, 12(2):102-108.
8. Binkley K., Davis A.E. Clinical, biochemical, and genetic characterization of a novel estrogen-dependent inherited form of angioedema. Journal of Allergy and Clinical Immunology 2000, 106(3):546-550.
9. Bork K., Barnstedt S., Koch P., Traupe H. Hereditary angioedema with normal C1-inhibitor activity in women. Lancet 2000, 356(9225):213-217.
10. Bork K., Kleist R., Hardt J., Witzke G. Kallikrein-kinin system and fibrinolysis in hereditary angioedema due to factor XII gene mutation Thr309Lys. Blood Coagulation and Fibrinolysis 2009, 20(5):325-332.
11. Bork K., Wulff K., Hardt J., Witzke G., Staubach P. Hereditary angioedema caused by missense mutations in the factor XII gene: Clinical features, trigger factors, and therapy. Journal of Allergy and Clinical Immunology 2009, 124(1):129-134.
12. Bouillet L., Boccon-Gibod I., Ponard D., Drouet C., Cesbron J., Dumestre-Perard C., et al. Bradykinin receptor 2 antagonist (icatibant) for hereditary angioedema type III attacks. Annals of Allergy, Asthma, and Immunology 2009, 103(5):448.
13. Boyle R., Nikpour M., Tang M. Hereditary angio-oedema in children: A management guideline. Pediatric Allergy and Immunology 2005, 16(4):288-294.
14. Bradford H.N., Dela Cadena R.A., Kunapuli S.P., Dong J.F., Lopez J.A., Colman R.W. Human kininogens regulate thrombin binding to platelets through the glycoprotein Ib-IX-V complex. Blood 1997, 90(4):1508-1515.
15. Cameron C.L., Fisslthaler B., Sherman A., Reddigari S., Silverberg M. Studies on contact activation: Effects of surface and inhibitors. Medical Progress through Technology 1989, 15(1-2):53-62.
16. Christiansen S.C., Proud D., Sarnoff R.B., Juergens U., Cochrane C.G., Zuraw B.L. Elevation of tissue kallikrein and kinin in the airways of asthmatic subjects after endobronchial allergen challenge. American Review of Respiratory Disease 1992, 145(4 Pt 1):900-905.
17. Chung D.W., Fujikawa K., McMullen B.A., Davie E.W. Human plasma prekallikrein, a zymogen to a serine protease that contains four tandem repeats. Biochemistry 1986, 25(9):2410-2417.
18. Cicardi M., Banerji A., Bracho F. Icatibant, a new bradykinin receptor antogonist in hereditary angioedema. Journal of the Energy Institute 2010, 363:532-541.
19. Cicardi M., Bork K., Caballero T., Craig T., Li H., Longhurst H., et al. Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: Consensus report of an International Working Group. Allergy 2012, 67(2):147-157.
20. Cicardi M., Igarashi T., Rosen F., Davis A. Molecular basis for the deficiency of complement 1 inhibitor in type I hereditary angioneurotic edema. Journal of Clinical Investigation 1987, 79(3):698-702.
21. Cicardi M., Levy R., McNeil D. Ecallantide for the treatment of acute attacks in hereditary angioedema. Journal of the Energy Institute 2010, 363:523-531.
22. Cichon S., Martin L., Hennies H., Muller F., Van Driessche K., Karpushova A., et al. Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III. American Journal of Human Genetics 2006, 79(6):1098-1104.
23. Cochrane C.G., Revak S.D. Dissemination of contact activation in plasma by plasma kallikrein. Journal of Experimental Medicine 1980, 152(3):608-619.
24. Cochrane C.G., Revak S.D., Wuepper K.D. Activation of Hageman factor in solid and fluid phases. A critical role of kallikrein. Journal of Experimental Medicine 1973, 138(6):1564-1583.
25. Colman R.W., Pixley R.A., Najamunnisa S., Yan W., Wang J., Mazar A., et al. Binding of high molecular weight kininogen to human endothelial cells is mediated via a site within domains 2 and 3 of the urokinase receptor. Journal of Clinical Investigation 1997, 100(6):1481-1487.
26. Colman R.W., Schmaier A.H. Contact system: A vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. Blood 1997, 90(10):3819-3843.
27. Cronin J., Maples K. Treatment of an acute attack of type III hereditary angioedema with ecallantide. Annals of Allergy, Asthma, and Immunology 2012, 108(1):61-62.
28. Crutchley D.J., Ryan J.W., Ryan U.S., Fisher G.H. Bradykinin-induced release of prostacyclin and thromboxanes from bovine pulmonary artery endothelial cells. Studies with lower homologs and calcium antagonists. Biochimica et Biophysica Acta 1983, 751(1):99-107.
29. Cugno M., Zanichelli A., Foieni F., Caccia S., Cicardi M. C1-inhibitor deficiency and angioedema: Molecular mechanisms and clinical progress. Trends in Molecular Medicine 2009, 15(2):69-78.
30. Curd J., Prograis L.J., Cochrane C. Detection of active kallikrein in induced blister fluids of hereditary angioedema patients. New England Journal of Medicine 1980, 152(3):742-747.
31. de Agostini A., Lijnen H.R., Pixley R.A., Colman R.W., Schapira M. Inactivation of factor XII active fragment in normal plasma. Predominant role of C-1-inhibitor. Journal of Clinical Investigation 1984, 73(6):1542-1549.
32. Dedio J., Jahnen-Dechent W., Bachmann M., Muller-Esterl W. The multiligand-binding protein gC1qR, putative C1q receptor, is a mitochondrial protein. Journal of Immunology 1998, 160(7):3534-3542.
33. Dedio J., Muller-Esterl W. Kininogen binding protein p33/gC1qR is localized in the vesicular fraction of endothelial cells. FEBS Letters 1996, 399(3):255-258.
34. Dewald G., Bork K. Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. Biochemical and Biophysical Research Communications 2006, 343(4):1286-1289.
35. Donaldson V.H., Rosen F.S., Bing D.H. Role of the second component of complement (C2) and plasmin in kinin release in hereditary angioneurotic edema (H.A.N.E.) plasma. Transactions of the Association of American Physicians 1977, 90:174-183.
36. Drouet C., Desormeaux A., Robillard J., Ponard D., Bouillet L., Martin L., et al. Metallopeptidase activities in hereditary angioedema: Effect of androgen prophylaxis on plasma aminopeptidase P. Journal of Allergy and Clinical Immunology 2008, 121(2):429-433.
37. Dunn J.T., Kaplan A.P. Formation and structure of human Hageman factor fragments. Journal of Clinical Investigation 1982, 70(3):627-631.
38. Dunn J.T., Silverberg M., Kaplan A.P. The cleavage and formation of activated human Hageman factor by autodigestion and by kallikrein. Journal of Biological Chemistry 1982, 257(4):1779-1784.
39. Erdos E., Sloane G. An enzyme in human plasma that inactivates bradykinin and kallidins. Biochemical Pharmacology 1962, 11:585-592.
40. Farkas H., Jakab L., Temesszentandrasi G., Visy B., Harmat G., Fust G., et al. Hereditary angioedema: A decade of human C1-inhibitor concentrate therapy. Journal of Allergy and Clinical Immunology 2007, 120(4):941-947.
41. Fernando L.P., Natesan S., Joseph K., Kaplan A.P. High molecular weight kininogen and factor XII binding to endothelial cells and astrocytes. Thrombosis and Haemostasis 2003, 90:787-795.
42. Fields T., Ghebrehiwet B., Kaplan A.P. Kinin formation in hereditary angioedema plasma: Evidence against kinin derivation from C2 and in support of "spontaneous" formation of bradykinin. Journal of Allergy and Clinical Immunology 1983, 72(1):54-60.
43. Frank M., Sergent J., Kane M., Alling D.W. Epsilon aminocaproic acid therapy of hereditary angioneurotic edema. A double-blind study. New England Journal of Medicine 1972, 286(15):808-812.
44. Fujikawa K., McMullen B.A. Amino acid sequence of human beta-factor XIIa. Journal of Biological Chemistry 1983, 258(18):10924-10933.
45. Gelfand J.A., Sherins R.J., Alling D.W., Frank M.M. Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities. New England Journal of Medicine 1976, 295(26):1444-1448.
46. Ghebrehiwet B., Lim B.L., Peerschke E.I., Willis A.C., Reid K.B. Isolation, cDNA cloning, and overexpression of a 33-kD cell surface glycoprotein that binds to the globular "heads" of C1q. Journal of Experimental Medicine 1994, 179(6):1809-1821.
47. Gigli I., Mason J.W., Colman R.W., Austen K.F. Interaction of plasma kallikrein with the C1 inhibitor. Journal of Immunology 1970, 104(3):574-581.
48. Ginsberg M.H., Jaques B., Cochrane C.G., Griffin J.H. Urate crystal-dependent cleavage of Hageman factor in human plasma and synovial fluid. Journal of Laboratory and Clinical Medicine 1980, 95(4):497-506.
49. Gounaris A.D., Brown M.A., Barrett A.J. Human plasma alpha-cysteine proteinase inhibitor. Purification by affinity chromatography, characterization and isolation of an active fragment. Biochemical Journal 1984, 221(2):445-452.
50. Grattan C., O'Donnell B., Francis D., Niimi N., Barlow R., Seed P., et al. Randomized double-blind study of cyclosporin in chronic 'idiopathic' urticaria. British Journal of Dermatology 2000, 143(2):365-372.
51. Greengard J.S., Griffin J.H. Receptors for high molecular weight kininogen on stimulated washed human platelets. Biochemistry 1984, 23(26):6863-6869.
52. Griffin J.H. Role of surface in surface-dependent activation of Hageman factor (blood coagulation factor XII). Proceedings of the National Academy of Sciences of the United States of America 1978, 75(4):1998-2002.
53. Griffin J.H., Cochrane C.G. Mechanisms for the involvement of high molecular weight kininogen in surface-dependent reactions of Hageman factor. Proceedings of the National Academy of Sciences of the United States of America 1976, 73(8):2554-2558.
54. Gustafson E.J., Schutsky D., Knight L.C., Schmaier A.H. High molecular weight kininogen binds to unstimulated platelets. Journal of Clinical Investigation 1986, 78(1):310-318.
55. Han E., MacFarlane R., Mulligan A., Scafidi J., Davis A.E. Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. Journal of Clinical Investigation 2002, 8(8):1057-1063.
56. Harpel P. Studies on human plasma alpha 2-macroglobulin-enzyme interactions. Evidence for proteolytic modification of the subunit chain structure. Journal of Experimental Medicine 1973, 138(3):508-521.
57. Harpel P., Lewin M., Kaplan A. Distribution of plasma kallikrein between C-1 inactivator and alpha 2-macroglobulin in plasma utilizing a new assay for alpha 2-macroglobulin-kallikrein complexes. Journal of Biological Chemistry 1985, 260(7):4257-4263.
58. Hasan A.A., Zhang J., Samuel M., Schmaier A.H. Conformational changes in low molecular weight kininogen alters its ability to bind to endothelial cells. Thrombosis and Haemostasis 1995, 74(4):1088-1095.
59. Hasan A.A., Zisman T., Schmaier A.H. Identification of cytokeratin 1 as a binding protein and presentation receptor for kininogens on endothelial cells. Proceedings of the National Academy of Sciences of the United States of America 1998, 95(7):3615-3620.
60. Herwald H., Dedio J., Kellner R., Loos M., Muller-Esterl W. Isolation and characterization of the kininogen-binding protein p33 from endothelial cells. Identity with the gC1q receptor. Journal of Biological Chemistry 1996, 271(22):13040-13047.
61. Herwald H., Hasan A.A., Godovac-Zimmermann J., Schmaier A.H., Muller-Esterl W. Identification of an endothelial cell binding site on kininogen domain D3. Journal of Biological Chemistry 1995, 270(24):14634-14642.
62. Hide M., Francis D., Grattan C., Hakimi J., Kochan J., Greaves M. Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. New England Journal of Medicine 1993, 328(22):1599-1604.
63. Higashiyama S., Ohkubo I., Ishiguro H., Kunimatsu M., Sawaki K., Sasaki M. Human high molecular weight kininogen as a thiol proteinase inhibitor: Presence of the entire inhibition capacity in the native form of heavy chain. Biochemistry 1986, 25(7):1669-1675.
64. Hojima Y., Cochrane C.G., Wiggins R.C., Austen K.F., Stevens R.L. In vitro activation of the contact (Hageman factor) system of plasma by heparin and chondroitin sulfate E. Blood 1984, 63(6):1453-1459.
65. Hosea S., Santaella M., Brown E., Berger M., Katusha K., Frank M. Long-term therapy of hereditary angioedema with danazol. Annals of Internal Medicine 1980, 93(6):809-812.
66. Ishiguro H., Higashiyama S., Ohkubo I., Sasaki M. Mapping of functional domains of human high molecular weight and low molecular weight kininogens using murine monoclonal antibodies. Biochemistry 1987, 26(22):7021-7029.
67. Jacobsen S. Separation of two separate substrates for plasma kinin forming enzymes. Nature 1966, 210:98-99.
68. Jong Y.J., Dalemar L.R., Seehra K., Baenziger N.L. Bradykinin receptor modulation in cellular models of aging and Alzheimer's disease. International Immunopharmacology 2002, 2(13-14):1833-1840.
69. Joseph K., Ghebrehiwet B., Kaplan A.P. Cytokeratin 1 and gC1qR mediate high molecular weight kininogen binding to endothelial cells. Clinical Immunology 1999, 92(3):246-255.
70. Joseph K., Ghebrehiwet B., Kaplan A.P. Activation of the kinin-forming cascade on the surface of endothelial cells. Biological Chemistry 2001, 382(1):71-75.
71. Joseph K., Ghebrehiwet B., Peerschke E.I., Reid K.B., Kaplan A.P. Identification of the zinc-dependent endothelial cell binding protein for high molecular weight kininogen and factor XII: Identity with the receptor that binds to the globular "heads" of C1q (gC1q-R). Proceedings of the National Academy of Sciences of the United States of America 1996, 93(16):8552-8557.
72. Joseph K., Kaplan A. Formation of bradykinin: A major contribution to the innate inflammatory response. Advances in Immunology 2005, 86:159-208.
73. Joseph K., Kaplan A. Factor XII independent activation of the bradykinin-forming cascade: Implications for the pathogenesis of Hereditary Angioedema Types I and II. Journal of Allergy and Clinical Immunology 2013, 132(2):470-475.
74. Joseph K., Nakazawa Y., Bahou W.F., Ghebrehiwet B., Kaplan A.P. Platelet glycoprotein Ib: A zinc-dependent binding protein for the heavy chain of high-molecular-weight kininogen. Molecular Medicine 1999, 5(8):555-563.
75. Joseph K., Shibayama Y., Ghebrehiwet B., Kaplan A.P. Factor XII-dependent contact activation on endothelial cells and binding proteins gC1qR and cytokeratin 1. Thrombosis and Haemostasis 2001, 85(1):119-124.
76. Joseph K., Shibayama Y., Nakazawa Y., Peerschke E.I., Ghebrehiwet B., Kaplan A.P. Interaction of factor XII and high molecular weight kininogen with cytokeratin 1 and gC1qR of vascular endothelial cells and with aggregated Abeta protein of Alzheimer's disease. Immunopharmacology 1999, 43(2-3):203-210.
77. Joseph K., Tholanikunnel B., Ghebrehiwet B., Kaplan A. Interaction of high molecular weight kininogen biding proteins on endothelial cells. Thrombosis and Haemostasis 2004, 91(1):61-70.
78. Joseph K., Tholanikunnel B., Kaplan A. Heat shock protein 90 catalyzes activation of the prekallikrein-kininogen complex in the absence of factor XII. Proceedings of the National Academy of Sciences of the United States of America 2002, 99(2):896-900.
79. Joseph K., Tholanikunnel B.G., Kaplan A.P. Activation of the bradykinin-forming cascade on endothelial cells: A role for heat shock protein 90. International Immunopharmacology 2002, 2(13-14):1851-1859.
80. Kaplan A. Urticaria and angioedema: Pathogenic mechanisms and treatment. Journal of Allergy and Clinical Immunology 2004, 114:415-424.
81. Kaplan A.P., Austen K.F. A pre-albumin activator of prekallikrein. Journal of Immunology 1970, 105(4):802-811.
82. Kaplan A.P., Austen K.F. A prealbumin activator of prekallikrein. II. Derivation of activators of prekallikrein from active Hageman factor by digestion with plasmin. Journal of Experimental Medicine 1971, 133(4):696-712.
83. Kaplan A., Finn A. Autoimmunity and the etiology of chronic urticaria. Canadian Journal of Allergy and Clinical Immunology 1999, 4:286-292.
84. Kaplan A., Ghebrehiwet B. Does C-2 kinin exist?. Journal of Allergy and Clinical Immunology 2004, 115(4):876.
85. Kaplan A., Greaves M. Angioedema. Journal of the American Academy of Dermatology 2005, 53:373-388.
86. Kaplan A., Joseph K., Maykut R., Geba G., Zeldin R. Treatment of chronic autoimmune urticaria with omalizumab. Journal of Allergy and Clinical Immunology 2008, 122(3):569-573.
87. Kaplan A.P., Joseph K., Shibayama Y., Reddigari S., Ghebrehiwet B., Silverberg M. The intrinsic coagulation/kinin-forming cascade: Assembly in plasma and cell surfaces in inflammation. Advances in Immunology 1997, 66:225-272.
88. Kellermann J., Lottspeich F., Henschen A., Muller-Esterl W. Completion of the primary structure of human high-molecular-mass kininogen. The amino acid sequence of the entire heavy chain and evidence for its evolution by gene triplication. European Journal of Biochemistry 1986, 154(2):471-478.
89. Kellermann J., Lottspeich F., Henschen A., Muller-Esterl W. Amino acid sequence of the light chain of human high molecular mass kininogen. Advances in Experimental Medicine and Biology 1986, 198(Pt A):85-89.
90. Kikuchi Y., Kaplan A. Mechanisms of autoimmune activation of basophils in chronic urticaria. Journal of Allergy and Clinical Immunology 2001, 107(6):1056-1062.
91. Kikuchi Y., Kaplan A. A role for C5a in augmenting IgG-dependent histamine release from basophils in chronic urticaria. Journal of Allergy and Clinical Immunology 2002, 109(1):114-118.
92. Kishimoto T., Viswanathan K., Ganguly T., Elankumaran S., Smith S., Pelzer K., et al. Contaminated heparin associated with adverse clinical events and activation of the contact system. Journal of the Energy Institute 2008, 358(23):2457-2467.
93. Kitamura N., Kitagawa H., Fukushima D., Takagaki Y., Miyata T., Nakanishi S. Structural organization of the human kininogen gene and a model for its evolution. Journal of Biological Chemistry 1985, 260(14):8610-8617.
94. Klemperer M.R., Donaldson V.H., Rosen F.S. Effect of C'1 esterase on vascular permeability in man: Studies in normal and complement-deficient individuals and in patients with hereditary angioneurotic edema. Journal of Clinical Investigation 1968, 47(3):604-611.
95. Kramer J., Rosen F., Colten H., Rajczy K., Strunk R. Transinhibition of C1 inhibitor synthesis in type I hereditary angioneurotic edema. Journal of Clinical Immunology 1993, 91(3):1258-1262.
96. Lin Y., Harris R.B., Yan W., McCrae K.R., Zhang H., Colman R.W. High molecular weight kininogen peptides inhibit the formation of kallikrein on endothelial cell surfaces and subsequent urokinase-dependent plasmin formation. Blood 1997, 90(2):690-697.
97. Lottspeich F., Kellermann J., Henschen A., Rauth G., Muller-Esterl W. Human low-molecular-mass kininogen. Amino-acid sequence of the light chain; homology with other protein sequences. European Journal of Biochemistry 1984, 142(2):227-232.
98. Lumry W., Li H., Levy R., Potter P., Farkas H., Moldovan D., et al. Randomized placebo-controlled trial of the bradykinin B2 receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: The FAST-3 trial. Annals of Allergy, Asthma, and Immunology 2011, 107(6):529-537.
99. Maas C., Govers-Riemslay J., Bouma B., Schiks B. Misfolded proteins activate Factor XII in humans, leading to kallikrein formation without initiating coagulation. Journal of Clinical Investigation 2008, 118:3208-3218.
100. Mahdi F., Madar Z.S., Figueroa C.D., Schmaier A.H. Factor XII interacts with the multiprotein assembly of urokinase plasminogen activator receptor, gC1qR, and cytokeratin 1 on endothelial cell membranes. Blood 2002, 99(10):3585-3596.
101. Mahdi F., Shariat-Madar Z., Schmaier A.H. The relative priority of prekallikrein and factors XI/XIa assembly on cultured endothelial cells. Journal of Biological Chemistry 2003, 278(45):43983-43990.
102. Mahdi F., Shariat-Madar Z., Todd R.F., Figueroa C.D., Schmaier A.H. Expression and colocalization of cytokeratin 1 and urokinase plasminogen activator receptor on endothelial cells. Blood 2001, 97(8):2342-2350.
103. Mandle R., Colman R., Kaplan A. Identification of prekallikrein and high-molecular-weight kininogen as a complex in human pl. Proceedings of the National Academy of Sciences of the United States of America 1976, 73(11):4179-4183.
104. Marceau F., Bachvarov D.R. Kinin receptors. Clinical Reviews in Allergy & Immunology 1998, 16(4):385-401.
105. Maurer M., Casale T., Hsieh H., Canvin J. Asteria II: Efficacy and safety results from a phase III randomized, double-blind, placebo-controlled trial of omalizumab in chronic idiopathic/spontaneous urticaria. Journal of the Energy Institute 2013, 368:924-935.
106. Meier H., Pierce J., Colman R., Kaplan A. Activation and function of human Hageman factor. The role of high molecular weight kininogen and prekallikrein. Journal of Clinical Investigation 1977, 60(1):18-31.
107. Mori K., Nagasawa S. Studies on human high molecular weight (HMW) kininogen. II. Structural change of HMW kininogen by the action of human plasma kallikrein. Journal of Biochemistry 1981, 89(5):1465-1473.
108. Mori K., Sakamoto W., Nagasawa S. Studies on human high molecular weight (HMW) kininogen. III. Cleavage of HMW kininogen by the action of human salivary kallikrein. Journal of Biochemistry 1981, 90(2):503-509.
109. Morrison D.C., Cochrane C.G. Direct evidence for Hageman factor (factor XII) activation by bacterial lipopolysaccharides (endotoxins). Journal of Experimental Medicine 1974, 140(3):797-811.
110. Motta G., Rojkjaer R., Hasan A.A., Cines D.B., Schmaier A.H. High molecular weight kininogen regulates prekallikrein assembly and activation on endothelial cells: A novel mechanism for contact activation. Blood 1998, 91(2):516-528.
111. Motta G., Shariat-Madar Z., Mahdi F., Sampaio C.A., Schmaier A.H. Assembly of high molecular weight kininogen and activation of prekallikrein on cell matrix. Thrombosis and Haemostasis 2001, 86(3):840-847.
112. Muller-Esterl W., Fritz H., Machleidt W., Ritonja A., Brzin J., Kotnik M., et al. Human plasma kininogens are identical with alpha-cysteine proteinase inhibitors. Evidence from immunological, enzymological and sequence data. FEBS Letters 1985, 182(2):310-314.
113. Muller-Esterl W., Rauth G., Lottspeich F., Kellermann J., Henschen A. Limited proteolysis of human low-molecular-mass kininogen by tissue kallikrein. Isolation and characterization of the heavy and the light chains. European Journal of Biochemistry 1985, 149(1):15-22.
114. Nakazawa Y., Joseph K., Kaplan A.P. Inhibition of contact activation by a kininogen peptide (HKH20) derived from domain 5. International Immunopharmacology 2002, 2(13-14):1875-1885.
115. Nishikawa K., Reddigari S.R., Silverberg M., Kuna P.B., Yago H., Nagaki Y., et al. Effect of Neurotropin on the activation of the plasma kallikrein-kinin system. Biochemical Pharmacology 1992, 43(6):1361-1369.
116. Noga O., Brunnee T., Schaper C., Kunkel G. Heparin, derived from the mast cells of human lungs is responsible for the generation of kinins in allergic reactions due to the activation of the contact system. International Archives of Allergy and Immunology 1999, 120(4):310-316.
117. Nussberger J., Cugno M., Amstutz C., Cicardi M., Pellacani A., Agostoni A. Plasma bradykinin in angioedema. Lancet 1998, 351(9117):1693-1697.
118. Nussberger J., Cugno M., Cicardi M., Agostoni A. Local bradykinin generation in hereditary angioedema. Journal of Allergy and Clinical Immunology 1999, 104(6):1321-1322.
119. Pappalardo E., Caccia S., Suffritti C., Tordai A., Zingale L., Cicardi M. Mutation screening of C1 inhibitor gene in 108 unrelated families with hereditary angioedema: Functional and structural correlates. Molecular Immunology 2008, 45(13):3536-3544.
120. Patston P., Gettins P., Beechem J., Schapira M. Mechanism of serpin action: Evidence that C1 inhibitor functions as a suicide substrate. Biochemistry 1991, 30(36):8876-8882.
121. Pixley R.A., Cassello A., De La Cadena R.A., Kaufman N., Colman R.W. Effect of heparin on the activation of factor XII and the contact system in plasma. Thrombosis and Haemostasis 1991, 66(5):540-547.
122. Pixley R., Schapira M., Colman R. The regulation of human factor XIIa by plasma proteinase inhibitors. Journal of Biological Chemistry 1985, 260(3):1723-1729.
123. Que B.G., Davie E.W. Characterization of a cDNA coding for human factor XII (Hageman factor). Biochemistry 1986, 25(7):1525-1528.
124. Reddigari S., Kaplan A.P. Cleavage of human high-molecular weight kininogen by purified kallikreins and upon contact activation of plasma. Blood 1988, 71(5):1334-1340.
125. Reddigari S., Kaplan A.P. Studies of the cleavage of human high molecular weight kininogen by purified plasma and tissue kallikreins, and upon contact activation of plasma. Advances in Experimental Medicine and Biology 1989, 247B:317-324.
126. Reddigari S.R., Kuna P., Miragliotta G., Shibayama Y., Nishikawa K., Kaplan A.P. Human high molecular weight kininogen binds to human umbilical vein endothelial cells via its heavy and light chains. Blood 1993, 81(5):1306-1311.
127. Reddigari S.R., Shibayama Y., Brunnee T., Kaplan A.P. Human Hageman factor (factor XII) and high molecular weight kininogen compete for the same binding site on human umbilical vein endothelial cells. Journal of Biological Chemistry 1993, 268(16):11982-11987.
128. Regoli D., Barabe J. Pharmacology of bradykinin and related kinins. Pharmacological Reviews 1980, 32(1):1-46.
129. Renne T., Dedio J., David G., Muller-Esterl W. High molecular weight kininogen utilizes heparan sulfate proteoglycans for accumulation on endothelial cells. Journal of Biological Chemistry 2000, 275(43):33688-33696.
130. Rojkjaer R., Hasan A.A., Motta G., Schousboe I., Schmaier A.H. Factor XII does not initiate prekallikrein activation on endothelial cells. Thrombosis and Haemostasis 1998, 80(1):74-81.
131. Rojkjaer R., Schmaier A.H. Activation of the plasma kallikrein/kinin system on endothelial cell membranes. Immunopharmacology 1999, 43(2-3):109-114.
132. Rojkjaer R., Schmaier A.H. Activation of the plasma kallikrein/kinin system on endothelial cells. Proceedings of the Association of American Physicians 1999, 111(3):220-227.
133. Saini S., Rosen K., Hsieh H., Wong D., Conner E., Kaplan A., et al. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. Journal of Allergy and Clinical Immunology 2011, 128(3):567-573.
134. Schapira M., Scott C.F., Colman R.W. Protection of human plasma kallikrein from inactivation by C1 inhibitor and other protease inhibitors. The role of high molecular weight kininogen. Biochemistry 1981, 20(10):2738-2743.
135. Schapira M., Scott C.F., Colman R.W. Contribution of plasma protease inhibitors to the inactivation of kallikrein in plasma. Journal of Clinical Investigation 1982, 69(2):462-468.
136. Schapira M., Scott C.F., James A., Silver L.D., Kueppers F., James H.L., et al. High molecular weight kininogen or its light chain protects human plasma kallikrein from inactivation by plasma protease inhibitors. Biochemistry 1982, 21(3):567-572.
137. Schmaier A.H. The kallikrein-kinin and the renin-angiotensin systems have a multilayered interaction. American Journal of Physiology-Regulatory Integrative and Comparative Physiology 2003, 285(1):R1-R13.
138. Schmaier A.H., Kuo A., Lundberg D., Murray S., Cines D.B. The expression of high molecular weight kininogen on human umbilical vein endothelial cells. Journal of Biological Chemistry 1988, 263(31):16327-16333.
139. Scott C.F., Colman R.W. Function and immunochemistry of prekallikrein-high molecular weight kininogen complex in plasma. Journal of Clinical Investigation 1980, 65(2):413-421.
140. Scott C.F., Schapira M., James H.L., Cohen A.B., Colman R.W. Inactivation of factor XIa by plasma protease inhibitors: Predominant role of alpha 1-protease inhibitor and protective effect of high molecular weight kininogen. Journal of Clinical Investigation 1982, 69(4):844-852.
141. Shariat-Madar Z., Mahdi F., Schmaier A.H. Mapping binding domains of kininogens on endothelial cell cytokeratin 1. Journal of Biological Chemistry 1999, 274(11):7137-7145.
142. Shariat-Madar Z., Mahdi F., Schmaier A. Identification and characterization of prolylcarboxypeptidase as an endothelial cell prekallikrein activator. Journal of Biological Chemistry 2002, 277(20):17962-17969.
143. Sheffer A., Austen K., Rosen F. Tranexamic acid therapy in hereditary angioneurotic edema. New England Journal of Medicine 1972, 287(9):452-454.
144. Sheffer A.L., Fearon D.T., Austen K.F. Clinical and biochemical effects of stanozolol therapy for hereditary angioedema. Journal of Allergy and Clinical Immunology 1981, 68(3):181-187.
145. Sheffer A., MacGinnitie A., Casapion M., Stolz L., Pullman W. Outcomes after ecallantide treatment of laryngeal hereditary angioedema attacks. Annals of Allergy, Asthma, and Immunology 2013, 110:184-188.
146. Sheikh I., Kaplan A. Studies of the digestion of bradykinin, Lys-bradykinin, and des-Arg9-bradykinin by angiotensin converting enzyme. Biochemical Pharmacology 1986, 35(12):1951-1956.
147. Sheikh I.A., Kaplan A.P. Studies of the digestion of bradykinin, lysyl bradykinin, and kinin-degradation products by carboxypeptidases A, B, and N. Biochemical Pharmacology 1986, 35(12):1957-1963.
148. Sheikh I.A., Kaplan A.P. The mechanism of degradation of bradykinin (lysyl-bradykinin) in human serum. Advances in Experimental Medicine and Biology 1989, 247A:331-336.
149. Sheikh I.A., Kaplan A.P. Mechanism of digestion of bradykinin and lysylbradykinin (kallidin) in human serum. Role of carboxypeptidase, angiotensin-converting enzyme and determination of final degradation products. Biochemical Pharmacology 1989, 38(6):993-1000.
150. Shibayama Y., Joseph K., Nakazawa Y., Ghebreihiwet B., Peerschke E.I., Kaplan A.P. Zinc-dependent activation of the plasma kinin-forming cascade by aggregated beta amyloid protein. Clinical Immunology 1999, 90(1):89-99.
151. Shoemaker L., Schurman S., Donaldson V., Davis A.E. Hereditary angioneurotic oedema: Characterization of plasma kinin and vascular permeability-enhancing activities. Clinical and Experimental Immunology 1994, 95(1):22-28.
152. Silverberg M., Kaplan A.P. Enzymatic activities of activated and zymogen forms of human Hageman factor (factor XII). Blood 1982, 60(1):64-70.
153. Silverberg M., Longo J., Kaplan A.P. Study of the effect of high molecular weight kininogen upon the fluid-phase inactivation of kallikrein by C1 inhibitor. Journal of Biological Chemistry 1986, 261(32):14965-14968.
154. Silverberg M., Nicoll J., Kaplan A. The mechanism by which the light chain of cleaved HMW-kininogen augments the activation of prekallikrein, factor XI and Hageman factor. Thrombosis Research 1980, 20(2):173-189.
155. Sloane D., Lee C., Sheffer A. Hereditary angioedema: Safety of long-term stanozolol therapy. Journal of Allergy and Clinical Immunology 2007, 120(3):654-658.
156. Smith D., Gilbert M., Owen W.G. Tissue plasminogen activator release in vivo in response to vasoactive agents. Blood 1985, 66(4):835-839.
157. Smith P., Kagey-Sobotka A., Bleecker E., Traystman R., Kaplan A., Gralnick H., et al. Physiologic manifestations of human anaphylaxis. Journal of Clinical Investigation 1980, 66(5):1072-1080.
158. Stewart J.M., Gera L., York E.J., Chan D.C., Bunn P. Bradykinin antagonists: Present progress and future prospects. Immunopharmacology 1999, 43(2-3):155-161.
159. Strang C., Auerbach H., Rosen F. C1s-induced vascular permeability in C2-deficient guinea pigs. Journal of Immunology 1986, 137(2):631-635.
160. Szeplaki G., Varga L., Valentin S., Kleiber M., Karadi I., Romics L., et al. Adverse effects of danazol prophylaxis on the lipid profiles of patients with hereditary angioedema. Journal of Allergy and Clinical Immunology 2005, 115(4):864-869.
161. Tait J.F., Fujikawa K. Identification of the binding site for plasma prekallikrein in human high molecular weight kininogen. A region from residues 185 to 224 of the kininogen light chain retains full binding activity. Journal of Biological Chemistry 1986, 261(33):15396-15401.
162. Tait J.F., Fujikawa K. Primary structure requirements for the binding of human high molecular weight kininogen to plasma prekallikrein and factor XI. Journal of Biological Chemistry 1987, 262(24):11651-11656.
163. Tankersley D.L., Finlayson J.S. Kinetics of activation and autoactivation of human factor XII. Biochemistry 1984, 23(2):273-279.
164. Thompson R., Mandle R.J., Kaplan A. Association of factor XI and high molecular weight kininogen in human plasma. Journal of Clinical Investigation 1977, 60(6):1376-1380.
165. Thompson R.E., Mandle R., Kaplan A.P. Studies of binding of prekallikrein and Factor XI to high molecular weight kininogen and its light chain. Proceedings of the National Academy of Sciences of the United States of America 1979, 76(10):4862-4866.
166. Tosi M. Molecular genetics of C1 inhibitor. Immunobiology 1998, 119(2):358-365.
167. van der Graaf F., Koedam J.A., Bouma B.N. Inactivation of kallikrein in human plasma. Journal of Clinical Investigation 1983, 71(1):149-158.
168. van der Graaf F., Koedam J.A., Griffin J.H., Bouma B.N. Interaction of human plasma kallikrein and its light chain with C1 inhibitor. Biochemistry 1983, 22(20):4860-4866.
169. van Iwaarden F., de Groot P.G., Bouma B.N. The binding of high molecular weight kininogen to cultured human endothelial cells. Journal of Biological Chemistry 1988, 263(10):4698-4703.
170. Vavrek R., Stewart J. Competitive antagonists of bradykinin. Peptides 1985, 6(2):161-164.
171. Wachtfogel Y.T., DeLa Cadena R.A., Kunapuli S.P., Rick L., Miller M., Schultze R.L., et al. High molecular weight kininogen binds to Mac-1 on neutrophils by its heavy chain (domain 3) and its light chain (domain 5). Journal of Biological Chemistry 1994, 269(30):19307-19312.
172. Wiggins R.C., Bouma B.N., Cochrane C.G., Griffin J.H. Role of high-molecular-weight kininogen in surface-binding and activation of coagulation Factor XI and prekallikrein. Proceedings of the National Academy of Sciences of the United States of America 1977, 74(10):4636-4640.
173. Zahedi R., Bissler J., Davis A.E., Andreadis C., Wisnieski J. Unique C1 inhibitor dysfunction in a kindred without angioedema. II. Identification of an Ala443 → Val substitution and functional analysis of the recombinant mutant protein. Journal of Clinical Investigation 1995, 95(3):1299-1305.
174. Ziccardi R.J. Spontaneous activation of the first component of human complement (C1) by an intramolecular autocatalytic mechanism. Journal of Immunology 1982, 128(6):2500-2504.
175. Zuraw B. Clinical practice. Hereditary angioedema. New England Journal of Medicine 2008, 359(10):1027-1036.
176. Zuraw B., Busse P., White M. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. Journal of the Energy Institute 2010, 363:513-522.